Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634645 · ClinicalTrials.gov registry record
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
A clinical trial of Esophageal Cancer and Barrett's Esophagus, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 4
- Study locations
NCT02634645 is a study of Esophageal Cancer and Barrett's Esophagus that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 5,000 participants, above the 458-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (992% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT02634645, a study of Esophageal Cancer and Barrett's Esophagus, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).
Conditions Studied
Interventions
- DRUG Chemotherapy
- RADIATION Radiation
- PROCEDURE Esophagectomy
- PROCEDURE Endoscopic eradication therapies (EET)
Study Locations (4)
California
- UCLA Medical Center - Los Angeles
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern Memorial Hospital - Chicago
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2015-01 |
| Est. Completion | 2027-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634645
The ClinicalTrials.gov registry entry for NCT02634645 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 458-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (992% higher). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Chemotherapy is the first listed.
NCT02634645 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02634645 about?
NCT02634645 is a clinical study titled "TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)". A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).
What is the current status of trial NCT02634645?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2015-01. Estimated completion is 2027-01.
What conditions does trial NCT02634645 study?
This clinical trial studies the following conditions: Esophageal Cancer, Barrett's Esophagus.
What interventions are being tested in trial NCT02634645?
The interventions under investigation include: Chemotherapy (DRUG), Radiation (RADIATION), Esophagectomy (PROCEDURE), Endoscopic eradication therapies (EET) (PROCEDURE).
Who is sponsoring clinical trial NCT02634645?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02634645 being conducted?
This trial has 4 study locations across California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Registry for Esophageal and Gastroesophageal Junction Cancer
RECRUITING
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Retrospective Review of Esophageal Cancer at MSKCC
RECRUITING
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.